RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MINNEMA MC
Collezione AOU Città della Salute di Torino

Items : 5

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X.

2025
AOU Città della Salute di Torino

Mina R; Mylin AK; Yokoyama H; Magen H; Alsdorf W; Minnema MC; Shune L; Isufi I; Harrison SJ; Shah UA; Schecter JM; Vogel M; Lendvai N; Gries KS; Katz EG; Slaughter A; Lonardi C; Gilbert J; Li Q; Deraedt W; Filho OC; Patel N; Florendo E; Karlin L; Weisel K;

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. in The Lancet. Oncology / Lancet Oncol. 2023 Oct;24(10):1119-1133. doi: 10.1016/S1470-2045(23)00405-9. Epub 2023 Sep 14.

2023
AOU Città della Salute di Torino

Benjamin R; Hájek R; Zweegman S; Silkjaer T; Caers J; Mancuso K; Tacchetti P; Razawy W; Grasso M; Giaccone L; Offidani M; Lund T; van der Velden VHJ; Pour L; Gadisseur A; Pietrantuono G; Broijl A; Roeloffzen WWH; Wu KL; Schjesvold F; van der Holt B; Minnema MC; van de Donk NWCJ; Vangsted AJ; Boccadoro M; Gay F; Sonneveld P; Musto P;

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. in HemaSphere / Hemasphere. 2022 Sep 30;6(10):e786. doi: 10.1097/HS9.0000000000000786. eCollection 2022 Oct.

2022
AOU Città della Salute di Torino

Sonneveld P; Zweegman S; Cavo M; Nasserinejad K; Broijl A; Troia R; Pour L; Croockewit S; Corradini P; Patriarca F; Wu K; Droogendijk J; Bos G; Hajek R; Teresa Petrucci M; Ypma P; Zojer N; Minnema MC; Boccadoro M;

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Nov 10;39(32):3613-3622. doi: 10.1200/JCO.21.01045. Epub 2021 Sep 14.

2021
AOU Città della Salute di Torino

Sonneveld P; Dimopoulos MA; Beksac M; van der Holt B; Aquino S; Ludwig H; Zweegman S; Zander T; Zamagni E; Wester R; Hajek R; Pantani L; Dozza L; Gay F; Cafro A; De Rosa L; Morelli A; Gregersen H; Gulbrandsen N; Cornelisse P; Troia R; Oliva S; van de Velden V; Wu K; Ypma PF; Bos G; Levin MD; Pour L; Driessen C; et alii...

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. in HemaSphere / Hemasphere. 2020 Aug 12;4(4):e370. doi: 10.1097/HS9.0000000000000370. eCollection 2020 Aug.

2020
AOU Città della Salute di Torino

Wester R; Zweegman S; van der Holt B; Kersten MJ; Vellenga E; van Marwijk-Kooy M; Asselbergs E; de Weerdt O; Minnema MC; Lonergan S; Palumbo A; Broijl A; Sonneveld P;